Riverwater Partners LLC Raises Stock Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Riverwater Partners LLC boosted its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 7.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 5,140 shares of the company’s stock after purchasing an additional 365 shares during the quarter. Riverwater Partners LLC’s holdings in Henry Schein were worth $356,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Smartleaf Asset Management LLC raised its holdings in Henry Schein by 23.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 759 shares of the company’s stock valued at $52,000 after acquiring an additional 143 shares in the last quarter. CIBC Asset Management Inc raised its stake in shares of Henry Schein by 1.0% in the 4th quarter. CIBC Asset Management Inc now owns 17,849 shares of the company’s stock valued at $1,235,000 after purchasing an additional 169 shares in the last quarter. Metis Global Partners LLC lifted its position in shares of Henry Schein by 4.7% during the fourth quarter. Metis Global Partners LLC now owns 4,203 shares of the company’s stock worth $291,000 after purchasing an additional 187 shares during the last quarter. Central Pacific Bank Trust Division grew its stake in Henry Schein by 2.0% in the fourth quarter. Central Pacific Bank Trust Division now owns 10,200 shares of the company’s stock worth $706,000 after purchasing an additional 200 shares in the last quarter. Finally, Sanctuary Advisors LLC increased its holdings in Henry Schein by 5.0% in the fourth quarter. Sanctuary Advisors LLC now owns 4,253 shares of the company’s stock valued at $294,000 after buying an additional 203 shares during the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

HSIC has been the topic of a number of research analyst reports. Wells Fargo & Company began coverage on Henry Schein in a report on Friday, February 14th. They set an “equal weight” rating and a $80.00 target price on the stock. Barrington Research restated an “outperform” rating and set a $90.00 price objective on shares of Henry Schein in a research note on Wednesday, February 26th. UBS Group lowered their target price on shares of Henry Schein from $83.00 to $80.00 and set a “neutral” rating for the company in a research note on Wednesday, February 26th. Bank of America upgraded shares of Henry Schein from an “underperform” rating to a “buy” rating and raised their price target for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Finally, Jefferies Financial Group boosted their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd. Six research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $81.10.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, Director Philip A. Laskawy sold 2,604 shares of the stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.04, for a total transaction of $184,988.16. Following the completion of the transaction, the director now directly owns 24,805 shares of the company’s stock, valued at approximately $1,762,147.20. This trade represents a 9.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bradford C. Connett sold 4,036 shares of the business’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the completion of the sale, the chief executive officer now directly owns 62,688 shares in the company, valued at $4,460,251.20. This represents a 6.05 % decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

Henry Schein Stock Performance

Shares of NASDAQ HSIC opened at $65.47 on Friday. Henry Schein, Inc. has a 12-month low of $63.00 and a 12-month high of $82.49. The company has a market cap of $8.13 billion, a PE ratio of 26.94, a P/E/G ratio of 2.13 and a beta of 0.84. The stock has a 50 day simple moving average of $73.96 and a 200-day simple moving average of $72.57. The company has a current ratio of 1.42, a quick ratio of 0.82 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same period in the previous year, the company posted $0.66 EPS. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. On average, equities research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current year.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.